We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world. https://lnkd.in/dj5gBmkF
About us
Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com.
- Website
-
http://www.leaptx.com
External link for Leap Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
Locations
-
Primary
Get directions
47 Thorndike St, Suite B1-1
Cambridge, MA 02141, US
Employees at Leap Therapeutics
Updates
-
March is Colorectal Cancer Awareness Month. Through our DeFianCe Phase 2 CRC clinical trial, we're reminded of the unmet medical need of these patients and the dedication from our clinical sites and physicians aiming for better outcomes. https://lnkd.in/e3S8CwVj
Colorectal Cancer
https://www.leaptx.com
-
Reminder to join Drs. Pelster & Wainberg today at 8:30 AM ET, for their firsthand accounts on DeFianCe, our 2L CRC trial of DKN-01 in combination with Bevacizumab and chemo. Link here: https://lnkd.in/ejiqtJ-9
-
Join us at ASCO GI 2024 for updates on Part A of our DeFianCe #colorectalcancer study at Moscone West on Jan 20th from 6:30-9:30AM PST at poster G8. Also, tune in on Jan 23, 8:30 am ET to hear insights from the treating physicians. Details and links:
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium | Leap Therapeutics, Inc.
investors.leaptx.com
-
Join us at J.P. Morgan’s 42nd Annual Healthcare Conference, 1/10/24, 1:30pm PT, to hear from our CEO Doug Onsi on Leap and our lead program, DKN-01. #JPM2024 https://lnkd.in/eemgN4wZ
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference | Leap Therapeutics, Inc.
investors.leaptx.com
-
BioSpace spotlights DKN-01 as one of “10 Promising Therapies for Hard-to-Treat Cancers.” With randomized controlled trials underway in GC and CRC, we are heading into an exciting phase of development and committed to bringing new therapies to patients. https://lnkd.in/dsFvNc9t
10 Promising Therapies for Hard-to-Treat Cancers | BioSpace
biospace.com
-
For more background on DKN-01 and our DeFianCe study in #colorectalcancer patients, read this interview with Dr. John Strickler of Duke University from earlier this year. Making a difference for CRC patients is our mission at Leap. https://lnkd.in/dTvyPWMU
DeFianCe: Assessing DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab in Advanced CRC
targetedonc.com
-
DKN-01 is moving into a second randomized controlled trial! This time in #colorectalcancer patients. Early efficacy data and high investigator/patient enthusiasm mark another milestone for DKN-01. Thank you to everyone involved in the DeFianCe study. https://lnkd.in/eue2FTw8